B7-2 + GM-CSF transduced autologous tumor cells

This product is an **autologous cancer vaccine** created by ex vivo retroviral transduction of a patient's own tumor cells with genes encoding the immune co-stimulatory molecule **B7-2 (CD86)** and the cytokine **granulocyte-macrophage colony-stimulating factor (GM-CSF)**[1][3]. After irradiation to prevent proliferation, the transduced cells are administered to the patient. The intended mechanism of action is to enhance anti-tumor immune responses by promoting antigen presentation and T-cell activation: - B7-2 provides an essential costimulatory signal for T cell activation. - GM-CSF promotes maturation and recruitment of dendritic cells and other antigen-presenting cells, facilitating efficiency of tumor antigen presentation to T cells[1][2]. This immunogene therapy approach has been tested as an experimental treatment for patients with **recurrent malignant gliomas** and **refractory melanomas**, but early clinical trials experienced technical challenges and limited patient accrual[1]. Developers are primarily academic investigators, with published trials from the University of Calgary and related research consortia[1].

Other names

B7-2/GM-CSF-transduced autologous tumor cellscombined B7-2 and GM-CSF immunogene therapy using autologous tumor cells